Roles of Sema4D and Plexin-B1 in tumor progression by Ch'ng, Ewe Seng & Kumanogoh, Atsushi
REVIEW Open Access
Roles of Sema4D and Plexin-B1 in tumor
progression
Ewe Seng Ch’ng
1*, Atsushi Kumanogoh
2
Abstract
Sema4D, also known as CD100, is a protein belonging to class IV semaphorin. Its physiologic roles in the immune
and nervous systems have been extensively explored. However, the roles of Sema4D have extended beyond these
traditionally studied territories. Via interaction with its high affinity receptor Plexin-B1, Sema4D-Plexin-B1 involve-
ment in tumor progression is strongly implied. Here, we critically review and delineate the Sema4D-Plexin-B1 inter-
action in many facets of tumor progression: tumor angiogenesis, regulation of tumor-associated macrophages and
control of invasive growth. We correlate the in vitro and in vivo experimental data with the clinical study out-
comes, and present a molecular mechanistic basis accounting for the intriguingly contradicting results from these
recent studies.
1. Introduction
Semaphorins are a large family of secreted, transmem-
brane or glycosylphosphatidylinositol-linked proteins
containing a phylogenetically conserved extracellular
“sema” domain. They are classified into eight classes, of
which classes 3 to 7 contain vertebrate semaphorins [1].
Their major receptors have been identified as plexins. In
contrast to semaphorins, plexins are transmembrane
proteins containing a phylogenetically conserved intra-
cellular “sex and plexins” domain. They are subdivided
into plexin A to D subfamilies [2].
Since the discovery of semaphorins as axon guidance
cues, semaphorin-plexin interactions have been tradi-
tionally best described in the nervous system. Recently
their interactions in other systems have also been
explored, notably in the cardiovascular development, fol-
lowing revelation of their regulatory roles in cellular
motility [3,4]. Intriguingly, semaphorins are also exten-
sively involved in immune response regulation, qualify-
ing some of them as “immune” semaphorins [5]. Recent
studies have also focused on the pathological aspects, in
particular on their links to several hallmarks of cancer
such as tumor angiogenesis and invasiveness. Indeed,
these processes recapitulate the many semaphorin-plexin
roles in physiologic development. Several recent reviews
nicely summarized the accumulating evidence of sema-
phorin-plexin involvement in cancer progression [6-9];
however, the majority of the content referred to particu-
larly secreted class 3 semaphorins. In this review, we
focus on a transmembrane class 4 semaphorin, Sema4D
and its receptor, plenxin-B1. We also present a molecu-
lar mechanistic basis to reconcile the conflicting results
of these molecules in tumor progression from the recent
studies.
2. Sema4D has versatile roles in immune
regulation and axonal guidance
Sema4D, also known as CD100, is a 150kD homodimeric
transmembrane glycoprotein first identified in immune
cells [10-12], and later classified as a member of class 4
semaphorin based on its distinctive structure [1].
Biological activities of Sema4D are well characterized
in the immune system. Sema4D is highly expressed in
resting T cells. Although its expression is low in resting
B cells and antigen-presenting cells, Sema4D is up-regu-
lated in these cells upon activation. As a ligand acting
via its low affinity receptor CD72, Sema4D promotes
the aggregation and survival of B cells, and enhances the
activation of B cells in antibody production [11,13,14].
Sema4D is also involved in the activation and matura-
tion of antigen-presenting cells [14,15]. Via its high affi-
nity receptor Plexin-B1 [2], Sema4D inhibits the
migration of monocytic and B-cell lineage cells [16,17].
Reciprocally, acting as a receptor, Sema4D regulates T
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stages of B cell differentiation [20].
Sema4D is also widely expressed in embryonic ner-
vous tissue, especially in cortical plate and dorsal root
ganglia [12], and postnatally in white matter, especially
in myelinating oligodendrocytes [21]. As an axonal gui-
dance cue in central nervous tissue, Sema4D functions
in a seemingly contradicting fashion. For example, it
induces growth cone collapse in primary hippocampal
neurons [22,23], but stimulates axonal outgrowth of
embryonic dorsal root ganglion neurons [24] and guides
the migratory process of gonadotropin hormone-releas-
ing hormone-1 cells [25]. Contradictory to its interac-
tion with CD72 in the immune system, Sema4D
interacts with its high affinity receptor, Plexin-B1, in the
nervous tissue.
However, cumulative data have suggested wider roles
for Sema4D. In vitro and in vivo studies recently have
given many insights into the involvement of Sema4D in
tumor progression via interaction with Plexin-B1 (Figure
1). The mechanistic roles of Sema4D and Plexin-B1 in
the tumor microenviroment such as tumor angiogenesis,
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Figure 1 Interaction of Sema4D and its receptors. Sema4D interacts with its low and high affinity receptors, CD72 and Plexin-B1, respectively
to elicit various physiologic responses as well as oncogenesis.
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Page 2 of 9regulation of tumor-associated macrophages as well as
the invasiveness of the tumor itself are highlighted in
the following discussion.
3. Sema4D acts as an angiogenic factor through
its high affinity receptor Plexin-B1
Evidence demonstrating the proangiogenic properties of
Sema4D has emerged from several in vitro and in vivo
studies. Sema4D is able to induce cell migration and
promote tubulogenesis in endothelial cells, mimicking
pivotal events in angiogenesis. Notably, this angiogenic
response elicited by Sema4D is comparable to that by
other well-known angiogenic molecules such as VEGF-
A, HGF, and bFGF and is independent of any up-regula-
tion of these molecules. In vivo studies employing chick
chorioallantoic membrane (CAM) assay and Matigel
plug assay confirmed this finding [26,27].
The signaling mechanism behind this Sema4D-
induced angiogenic response has also been extensively
studied. Plexin-B1, a high affinity receptor for Sema4D,
is highly expressed in endothelial cells. Sema4D specifi-
cally binds and activates this endothelial receptor to eli-
cit an angiogenic effect [26,27]. However, the signaling
cascade beyond the Sema4D-Plexin-B1 interaction is
complex and is still debated as described below.
Regarding the angiogenic process, two mechanisms
have been proposed with conflicting results (Figure 2.).
One mechanism proposes a signaling mechanism utiliz-
ing the C-terminal PDZ-binding motif of Plexin-B1,
w h i c hb i n d st w oR h o G E F s ,P D Z - R h o G E Fa n dL A R G ,
and subsequently activates RhoA. Through the engage-
ment of integrins, this pathway also activates an intra-
cellular tyrosine kinase cascade, notably one that
involves Pyk2 [27-29]. The other proposed mechanism
involves Met activation and tyrosine phosphorylation
through Plexin-B1-Met interaction upon Sema4D bind-
ing [26]. Both of these mechanisms lead to cytoskeletal
reorganization in endothelial cells and their migration.
Given its proangiogenic properties, the possible invol-
vement of Sema4D in tumor angiogenesis was explored.
Sema4D is indeed highly expressed in a wide range of
human tumors such as prostate, colon, breast, oral, head
and neck carcinomas as well as soft tissue sarcomas
[30,31]. In one study employing head and neck squa-
mous cell carcinoma cell lines with high expression of
Sema4D, tumor growth and tumor angiogenesis in vivo
were greatly impaired in the absence of Sema4D [31]. In
addition, induction of angiogenesis by tumor cells was
made possible by proteolytic cleavage of this membrane-
bound Sema4D from the tumor cell surface, releasing its
soluble form and thereby permitting Sema4D to act on
local as well as distant tumor microenvironments [32].
Another study employing breast cancer cell lines in
Sema4D knockout mice demonstrated that the
presence of Sema4D in the tumor microenvironment is
important for tumor growth and metastasis, which is
attributed to tumor vessel maturation induced by
Sema4D [33]. Contradicting to the role of tumor-
derived Sema4D in head and neck squamous cell carci-
noma, this study however showed that tumor-asso-
ciated macrophages but not tumor cells per se are the
main cells that produce Sema4D in the tumor micro-
environment, which enhances angiogenesis and contri-
butes to tumor growth [33]. This discrepancy remains
unsolved possibly due to differences between these
tumor cell lines.
Similar to other in vitro studies, tumor angiogenesis
induction by Sema4D is mediated through its interac-
tion with Plexin-B1 [31] (Figure 2). A study using
Sema4D-expressing melanoma transplants in Plexin-
B1 knockout mice, however, showed no significant
impairment in tumor angiogenesis. This result indi-
cated that Plexin-B1 is sufficient but not essential for
Sema4D-induced tumor angiogenesis; possibly the
redundant lower affinity receptors such as Plexin-B2
could be engaged by Sema4D in tumor angiogenesis
[34] (Figure 2).
4. Sema4D regulates monocytic lineage cells and
tumor-associated macrophages in tumor
microenvironment
Focusing on the effect of Sema4D on a monocytic line-
age, an inhibitory effect on cell migration was demon-
strated [16]. A recent study also showed that sequential
engagement of CD72 and Plexin-B1 is crucial in this
inhibitory effect during the maturation of monocytes
into immature dendritic cells. Modulation of cytokine
production towards either an anti-inflammatory or a
pro-inflammatory cytokine profile seems to be depen-
dent on Sema4D concentration [14,17]. Upon activation,
Sema4D expression in dendritic cells is up-regulated.
Augmentation of response in an autocrine manner by
the proteolytic release of Sema4D acting on receptors in
t h es a m ec e l l sc o u l de n s u e[ 15]. In tumor-associated
macrophages, although the lack of Sema4D itself did not
alter the differentiation and activation capabilities as
well as the cytokine production profile, a significantly
lower number of tumor-associated macrophages was
observed in the tumor microenvironment [33]. However,
the precise mechanism behind these findings awaits
elucidation.
Considering these results, the inhibition of cell migra-
tion by Sema4D could be alternately interpreted as a
means of prolonging cell-cell contact in a physiologic
immune response. Exploitation of this mechanism by
tumor cells would lead to the retention of tumor-asso-
ciated macrophages and the subsequent induction of
angiogenesis could therefore be triggered.
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growth
Invasive growth is a complex morphogenetic program
that includes several steps such as cell-cell dissociation,
motility, colonization of new sites, proliferation and sur-
vival. Invasive growth under physiologic conditions
occurs during embryogenesis and wound healing. How-
ever, when this program is hijacked, cancer progression
and metastasis, the pathologic counterpart, ensue [35].
An invasive growth phenotype in epithelial cells could
be elicited by Sema4D through Plexin-B1 coupled with
the Met signaling pathway [36]. Another study along the
same line showed that Ron, a scatter factor receptor
similar to Met, also couples with Plexin-B1 in transdu-
cing Sema4D signals (Figure 3). Moreover, over-expres-
sion of Plexin-B1 is observed in breast, colon, liver,
pancreatic and gastric carcinoma cell lines. Signaling
through Plexin-B1 coupled with Met is essential for
invasive response in these cell lines [26,37,38].
However, signaling by Sema4D through Plexin-B1
coupling with Met in invasive response is partially dis-
puted by a recent study. This study demonstrated that
the antimigratory or promigratory effects of Sema4D in
breast cancer cell lines depend on the stoichiometry of
the expression of Plexin-B1, Met and ErbB-2 [39]. ErbB-
2 is a well-known poor prognostic factor in breast can-
cer. Coupling of Plexin-B1 with Met inhibits migration,
while coupling with ErbB-2 promotes it. By competing
for Plexin-B1, these two molecules counter each other’s
effects in the same tumor cell, determining the net anti-
migratory or promigratory effect of Sema4D. These
molecular complexes further control a downstream
Figure 2 Sema4D-Plexin-B1 signaling pathways in angiogenesis. Sema4D engages Plexin-B1 to induce angiogenesis and tumor
angiogenesis via two independent downstream pathways. Plexin-B2 might also play a redundant role in this aspect.
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ism proposed to promote endothelial cell angiogenesis
[39,40] (Figure 3).
Although not shown in most studies involving cancer
cell lines, another line of investigation of Sema4D and
Plexin-B1 interactions centered on the collapse of neur-
ite outgrowth. Recently, Plexin-B1 has been discovered
to have intrinsic GTPase-activating protein (GAP) activ-
ity towards R-Ras [23]. Inactivation of R-Ras reduces
cell adhesion, cell migration, and growth cone out-
growth [41]. In contrast to the activating pathways dis-
cussed above, this inhibitory pathway is believed to
inhibit cancer cell migration. Mutations that abolish the
R-Ras GAP activity of Plexin-B1 in cell lines promote
cell adhesion, motility and invasion [42] (Figure 4).
6. High expression of Sema4D is a poor
prognostic factor in soft tissue sarcomas
Cumulative evidence regarding the roles of Sema4D-
Plexin-B1 interaction in tumor progression came from
in vitro and in vivo studies. A recent clinical study on
soft tissue sarcomas revealed that higher Sema4D
expression was correlated with higher mitotic counts,
cellularity, a higher necrosis ratio and Ki-67 index [30],
suggesting a proliferative advantage in tumors with
higher Sema4D expression. Accordingly, higher Sema4D
Figure 3 Control of cellular motility by Sema 4D-Plexin-B1 interation via the coopeative mechanism. Coupled with the Met, Ron or ErbB-
2 tyrosine kinase receptor at the cellular membrane surface, Sema4D interacts with Plexin-B1 to control cellular motility and invasive growth via
Gab1 or Rho-dependant pathways.
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disease-free survival [30] (Table 1). Similarly, via activa-
tion by Plexin-B1, Sema4D-expressing CD38+ B-cell
chronic lymphocytic leukemic cells have better viability
and a higher proliferative rate [43].
7. Clinical studies offer insights into the role of
Plexin-B1 in human oncogenesis
Recently clinical studies have also provided further
insights into the significance of Plexin-B1 in human
cancers (Table 1.). In human breast cancers, gene
expression microarray analysis showed that low Plexin-
B1 expression was associated with high histologic grad-
ing, ErbB-2 over-expression and a high proliferative
index in estrogen receptor-positive breast cancers. Low
Plexin-B1 expression also predicts poor outcome in
terms of disease-free survival in estrogen receptor-posi-
tive breast cancers [44,45]. Similarly, Plexin-B1
expression is also down-regulated in renal cell carcino-
mas where 169 out of 209 carcinomas showed negativity
in a recent report. Reintroducing Plexin-B1 into the
renal adenocarcinoma cell line reduced the proliferative
rate [46]. These results imply a tumor suppressor role of
Plexin-B1 in oncogenesis.
In contrast, a recent study on human breast and ovar-
ian cancers using immunohistochemistry showed that
co-expression of Plexin-B1 and Met was significantly
associated with a higher tumor grade and lymph node
metastasis. Met was activated in the presence of Plexin-
B1 expression in a majority of these cancers [47]. In
human prostate cancers, Plexin-B1 and Sema4D are
strongly associated and highly expressed compared to
the non-neoplastic tissue (77% versus 6% and 58% ver-
sus 3.5% respectively). Mutations in Plexin-B1 are fre-
quently detected in primary and metastatic prostate
cancers [42]. Among the mutations, the more frequent
Figure 4 Control of cellular motility by Sema 4D-Plexin-B1 interation via the intrinsic mechanism. Decreased intrinsic GAP activity of
Plexin-B1 also leads to preferential signaling through the stimulatory R-Ras and Rho-dependant pathways.
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binding domain of Plexin-B1. Structural analysis
revealed a reduced Rho GTPase binding affinity in some
of these mutations [48]. In vitro studies showed that
these mutations impaired the R-RasGAP activity of
Plexin-B1, leading to increased cell adhesion, motility
and invasion [42]. These results instead suggest an
oncogenic nature of Plexin-B1. Interestingly, a recent
study on melanoma also revealed contradicting effects
of Plexin-B1 expression on cell migration: enhancement
in primary tumor cells but inhibition in metastatic
tumor cells [49].
8. Intrinsic and cooperative mechanisms
determine the overall signaling of Plexin-B1 in
tumor progression
Recognizing the fact that both the stimulatory and inhi-
bitory domains coexist in the Plexin-B1 cytoplasmic
domain, we speculate that “intra-molecular” preferential
Plexin-B1 signaling pathways in cancers could constitute
a sound explanation to reconcile these conflicting clini-
cal results of Plexin-B1 in tumor progression. Inhibitory
signals of Plexin-B1 would enable it to function as a
tumor suppressor gene as implied from the breast and
renal cancer studies [44-46]. In contrast, impairment in
the Plexin-B1 inhibitory pathway due to mutation,
together with over-expression of Plexin-B1 would allow
its stimulatory signals to prevail and act as an oncogene
such as in prostate cancer [42].
In addition, fine-tuning the inhibitory or stimulatory
downstream signaling of Plexin-B1 is possible through
the association with competing receptor tyrosine kinases
such as Met and ErbB-2, which in turn would deliver
additional signals. Although a recent study on human
breast and ovarian cancers implies that Plexin-B1 func-
tions as an oncogene when coupled with Met activation
[47], involvement of ErbB-2 in this association has yet
to be addressed in clinical studies. The available in vitro
data, nonetheless, support the ErbB-2 instead of Met
coupling in determining the invasiveness of tumor cell
lines [39,40].
Conclusion and perspective
Although the interaction of Sema4D and Plexin-B1 has
profound physiologic effects in the immune and nervous
systems, emerging data suggests their involvement in
tumor progression and especially in tumor angiogenesis
where Sema4D acts as a proangiogenic factor via Plexin-
B1. Over-expression of Sema4D in tumor confers on the
tumor cells a selective proliferative advantage. Sema4D
might also influence via Plexin-B1 several functional
aspects of tumor-associated macrophages such as their
migratory capability and capability to induce tumor
angiogenesis. In contrast to responses elicited in non-
tumorous components such as endothelial cells and
macrophages, signaling through Plexin-B1 in various
cancers gives rise to seemingly contradicting responses,
as highlighted in this review. Current results suggest
that either the stimulatory or inhibitory signaling could
be induced via the respective stimulatory or inhibitory
domain in the Plexin-B1 molecule itself. This could also
be achieved via association with the competing receptor
tyrosine kinases such as Met and ErbB-2 (Figure 3 and
4). This double-checkpoint mechanism based on intrin-
sic and cooperative signaling signifies the complexity
and importance of Plexin-B1 signaling in tumor progres-
sion. Further studies will certainly solidify the basis for
these unique mechanisms.
List of abbreviations
VEGF: vascular endothelial growth factor; HGF: hepatocyte growth factor;
bFGF: basic fibroblast growth factor; PDZ: PSD-95/Dlg/ZO-1; GEF: guanine
nucleotide exchange factor; LARG: leukemia-associated Rho GEF; Pyk2:
Table 1 Important findings regarding expression of Sema4D and Plexin-B1 in various human cancers
Cancer Type Findings Prognosis
Soft tissue sarcomas [30] Higher Sema4D expression was associated with higher
mitotic counts, cellularity, necrotic ratio and Ki-67 index
Poorer overall survival and disease-free survival with
higher Sema4D expression
B-cell chronic lymphocytic
leukemia [43]
Sema4D-expressing CD38+ B-CLL cells showed increased
proliferation and survival.
Not available
Breast carcinoma [44,45] Lower Plexin-B1 was associated with a higher histologic
grade, proliferative index and ErbB-2 expression in
estrogen receptor-positive cases
Poorer disease-free survival with lower Plexin-B1
expression in estrogen receptor- positive cases
Renal cell carcinoma [46] 81% of renal cell carcinoma lost the plexin-B1 expression Not available
Breast and Ovarian Carcinomas
[47]
Co-expression of Plexin-B1 and Met resulted in Met
activation and was associated with a higher tumor grade
and lymph node metastasis
Not available
Prostate adenocarcinoma [42] Expression of Plexin-B1 and Sema4D was significantly
correlated and both were highly expressed in cancer
cases (77% and 58% respectively)
Not available
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Page 7 of 9Proline-rich tyrosine kinase 2; MET: mesenchymal-epithelial transition factor;
Ron: Recepteur d’origine Nantais; GAP: GTPase-activating protein.
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